**Tepezza® (Teprotumumab)**Referring Physician Order Form
Please fax completed referral form & all required documents to 208-595-4427



		PATIENT D	EMOGRAPH	IICS					
Patient Name:			DOB:		Phone:				
Address:			City/ST/Zip:						
Allergies:			$\square$ NKDA	Weight:	□ lbs □ kg	Height:	□ in □ cm		
Patient Status:	☐ New to Therapy	☐ Dose or Frequency Chan	ge □ Orde	er Renewal					
INSURANCE INFORMATION: Please attach copy of insurance card (front and back).									
DIAGNOSIS*									
*ICD 10 Code  Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm, ICD10: E05.00									
Required	☐ Other:		ICI	D10:					
INFUSION ORDERS									
MEDICATION		DOSE		DIRECTIONS/DURATION					
Tepezza® (teprotumumab)		☐ Initial Dose: mg (10 mg/kg)	☐ Initial: Infuse IV over 90 minutes x 1 dose. ☐ Subsequent: Infuse IV over 90 minutes every 3 weeks x doses.						
		□ Subsequent Doses:	Gubsequent: Illiuse IV over 30 Illi				nutes every 3 weeks x doses. (maximum 7)		
		mg (20 mg/kg)	*If first 2 infusions are well tolerated, may reduce subsequent infusion times to over 60 minutes.			times to			
Is patient currently receiving therapy above from  If yes, Facility Name:									
another facility?									
☐ Yes ☐ No		Date of las	t treatment:Date of next treatment:						
PRE-MEDICATI	ON ORDERS		LAB ORDE	RS					
☐ No premeds or	rdered at this time		Labs to be d	rawn by:	☐ Infusion Center	☐ Referrin	g Physician		
☐ Acetaminophe	n 650mg PO	☐ Diphenhydramine 25mg PO	☐ No labs o	rdered at this ti	me				
☐ Methylpredniso	olone 40mg IVP -OR-	☐ Hydrocortisone 100mg IVP	☐ Blood glu	cose q	CBC with	h diff/platelet q			
☐ Other:			☐ CMP q _						
REFERRING PHYSICIAN INFORMATION									
Physician Signatu	re:				Date:				
		Provider NPI:							
Contact Person:		Phone #:			Fax #:				
Email Where Follow Up Documentation Should Be Sent:									
REQUIRED CLINICAL DOCUMENTATION									
Please attach medical records: Initial H&P, current MD progress notes, medication list, and labs/test results to support diagnosis.									
☐ See Attached Medical Records									
☐ Yes ☐ No Is active Thyroid Eye Disease (TED) confirmed with a baseline Clinical Activity Score (CAS) of ≥ 4 in the more severely affected eye?									
☐ Yes ☐ No Does the patient present with at least ONE of the following features of moderate-to-severe TED? If yes, please select all that apply:									
☐ Lid retraction ≥ 2mm									
	<ul> <li>☐ Moderate or severe soft tissue involvement</li> <li>☐ Exophthalmos ≥ 3mm above normal for race and gender</li> <li>☐ Intermittent or constant diplopia</li> </ul>								
	☐ Other:								
Yes No Is patient euthyroid or currently receiving treatment to correct mild hypo- or hyperthyroidism (e.g., free T4 and free T3 levels are < 50% above or below normal limits)?									
LAB AND TEST F	RESULTS (required)								
		Activity Score (CAS) report							
•	, ,	e [T4], free triiodothyronine [T3])							
PRIOR FAILED	THERAPIES								
Medication Failed	l:	Dates of Trea	tment:		Reason for D/	C:			
Medication Failed	l:	Dates of Trea	tment:		Reason for D/	C:			
Medication Failed:		Dates of Trea	eatment:Reason for D/C:						
Medication Failed	l:	Dates of Trea	tment:		Reason for D/	Reason for D/C:			